Log in to search using one of your social media accounts:


Pertuzumab gets NICE approval in advanced breast cancer

New drug  approved for routine use in the NHS in England for women with HER2-positive metastatic or recurrent inoperable breast cancer
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research

Related Links:

This study provides molecular basis for significantly increased cardiotoxicity in cancer patients who are treated with anthracyclines and trastuzumab-based combination regimens. PMID: 29464058 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Authors: Kim YG, Yoon YN, Choi HS, Kim JH, Seol H, Lee JK, Seong MK, Park IC, Kim KI, Kim HA, Kim JS, Noh WC Abstract Although it has been proposed that the beneficial effect of HER2-targeted therapy in HER2-negative breast cancer is associated with the molecular subtype conversion, the underlying mechanism and the clinical biomarkers are unclear. Our study showed that breast cancer stem cells (BCSCs) mediated HER2 subtype conversion and radioresistance in HER2-negative breast cancer cells and evaluated serum HER2 as a clinical biomarker for HER2 subtype conversion. We found that the CD44+/CD24-/low BCSCs from HER2...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The objective of this retrospective chart review study was to compare the prognostic outcomes between two types of patients with hormone receptor-positive (HR+), HER2-negative (HER2–) breast cancer. Patients and Methods: We estimated overall survival of the two groups and evaluated the progressive course of the disease using disease-free interval (DFI) and interval from the end of adjuvant treatment to the first recurrence (AFI). Results: We studied 172 patients with HR+/HER2– breast cancer, of which 65 were de novo and 107 were recurrent. Median OS between de novo and recurrent BC was 4.85 and 3.45 years, resp...
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
In conclusion, the incidence and prognosis of BCLM varied by tumor subtypes, age, and race. Elderly patients with HER2‐positive or triple‐negative tumors were more likely to have BCLM. The aim of this study was to assess the incidence and survival in patients with breast cancer and lung metastases (BCLM) and associated risk factors on a population level. Of the 11,568 patients with stage IV breast cancer, 4213 (36.42%) had BCLM and 1214 (10.49%) had BCLM confined to lungs. Survival analysis showed that the aged, black race, HR−/HER2+, triple‐negative subtype, higher grade were the independent risk factor for B...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
AbstarctPage 95, Table  2, final row, second column: the mean Advanced treatment annual cost which
Source: PharmacoEconomics - Category: Health Management Source Type: research
Authors: Burris HA Abstract INTRODUCTION: The emergence of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors marked a significant advancement in the treatment of advanced breast cancer. Ribociclib is an orally bioavailable, highly selective inhibitor of CDK4/6. In combination with various endocrine therapies, ribociclib has demonstrated clinical activity as a first-line therapy for patients with HR+, HER2- advanced breast cancer, without compromising the favorable toxicity profile associated with endocrine therapy. Thus, ribociclib is now considered a new standard of care for HR+, HER2- advanced breast cancer. A...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
ConclusionAlthough the study was terminated owing to the altered liver function, it showed that there was a trend to greater shrinkage of tumor in the combination group for ER-positive, HER2-negative postmenopausal breast cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Abstract AimsA better understanding of the expression of cancer testis antigens (CTA) in breast cancer might identify new immunotherapy options, especially for triple‐negative (TN) tumours, which lack expression of conventional therapeutic targets ER, PR and HER2 (receptors for Oestrogen, Progesterone and Human epidermal growth factor). The aim of this study was to quantify the expression of MAGE‐A and NY‐ESO‐1 CTAs in breast cancer, and relate this to known clinicopathologic parameters. Methods and resultsWe surveyed MAGE‐A and NY‐ESO‐1 protein expression in an unselected cohort of 367 breast tumours (out o...
Source: Histopathology - Category: Pathology Authors: Tags: Original Article Source Type: research
ConclusionThis novel human breast cancer-bone metastasis cell line will be a useful model to study aspects of breast cancer biology, particularly metastasis-related changes from breast to bone.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | National Institute for Health and Clinical Excelle | Women